Aman's Global Market Intelligence

Executive dashboard

S&P 500 · Tue7,677.28+0.32%

Nasdaq · Tue26,151.30+0.66%

Dow · Tue53,577.40+0.30%

Russell 2000 · Tue3,010.02+0.50%

VIX · Tue15.45−0.40 point vs Mon

U.S. futures · 08:23ES −0.12%NQ −0.23% · YM +0.02%

U.S. 2Y / 10Y4.199% / 4.649%−0.5 / +1.0 bp

Dollar index98.998+0.08%

WTI Oct / Gold Dec$80.76 / $4,688.20−1.94% / −0.13%

Nikkei / Hang Seng66,240 / 25,731+0.58% / +0.86%

Shanghai / KOSPI3,913 / 6,826+0.62% / +1.23%

Europe · Tue closeSTOXX 600 656.48DAX 26,266 · FTSE 10,886 · CAC 8,439

1 · Macro

Two 08:30 ET releases can move rates

BEA schedules Q2 GDP second estimate/corporate profits and July personal income/outlays together at 14:30 CEST. The report is written six hours earlier: no result is assumed. BEA schedule

2 · AI event

NVIDIA is the cross-theme pivot

Nasdaq lists NVIDIA after the close with a $2.09 EPS forecast from 12 estimates. That figure is vendor consensus—not company guidance. NVDA rebounded 2.19% Tuesday, but NQ futures now slip. Nasdaq earnings calendar

3 · Oil

Sanctions path lowers immediate supply premium

WTI is down 1.94% as investors assess Washington's economic-pressure approach toward Iran rather than immediate military escalation. Hormuz and sanctions headlines can still produce abrupt reversals. CNBC

Market drivers

Macro, central banks and geopolitics

Event before inference: the day's GDP/profits and income/outlays releases arrive at 14:30 CEST. Directional positions before them are exposed to simultaneous growth, inflation and income revisions. BEA
Rates are mixed, not easy: the 2Y is 4.199% while the 10Y is 4.649%, a roughly +45 bp curve. The long yield remains a demanding discount rate for high-duration themes even after Tuesday's equity rebound. 10Y · 2Y
Fed update: the Board published minutes of its July 20 and July 29 discount-rate meetings on Aug. 25. This is not a new FOMC rate decision; the next scheduled FOMC is Sep. 15–16. Fed release · calendar
Geopolitical cross-currents: WTI's drop signals less immediate supply fear, while Canada announced retaliatory tariffs on about $20B of U.S. goods. Tariff and Iran/Hormuz headlines remain gap risks. Canada

Earnings, regulation and rotation

Tuesday repair was broad: Nasdaq +0.66%, Russell +0.50%, S&P +0.32% and Dow +0.30%; VIX eased to 15.45. Futures do not confirm follow-through yet. S&P · Cboe VIX
AI divergence: AMD +4.91%, MRVL +4.84%, NVDA +2.19% and ANET +1.48%, versus AVGO −0.56% and VRT +0.31%. The split argues for confirmation, not a blanket semiconductor bet. NVDA · ANET
After-close cluster: NVIDIA, CrowdStrike, Salesforce and Synopsys report tonight; Marvell follows Aug. 27. Guidance and post-gap holds matter more than consensus beats alone. Aug. 26 · Aug. 27
Infrastructure organization risk: CNBC reports OpenAI's data-center chief departed after an infrastructure reorganization. This does not establish lower capex, but it raises execution/governance questions for a major ecosystem buyer. CNBC

Theme dashboards

AI · binary event

Repair, then a major information reset

Leaders: AMD +4.91%, MRVL +4.84%, NVDA +2.19%, ANET +1.48%. ANET's relative strength survived two sessions, but NVIDIA's guide can reprice Ethernet, accelerators, custom silicon, power and cooling together.
Laggards: AVGO −0.56% and VRT +0.31% underperformed Nasdaq +0.66%. OpenAI's infrastructure reorganization is an execution signal, not evidence of canceled demand.
Risk: high expectations, 4.65% 10Y, export controls, customer concentration, power/interconnection bottlenecks and event gaps. Do not infer tomorrow's capex from one earnings print.

Quantum · highly speculative

Small rebound; new CFO transition at D-Wave

Tuesday: QBTS +3.59%, RGTI +3.48%, QUBT +2.67% and IONQ +2.41% after Monday's 7.6%–8.6% losses. The bounce recovered only part of the decline.
Primary filing: D-Wave's Aug. 25 8-K says CFO John Markovich will retire effective Sep. 2; SVP Finance Greg Golkov becomes acting CFO. The company explicitly says the resignation was not due to a disagreement. SEC 8-K
Risk: commercialization, architecture, valuation, cash burn/dilution, management transition and squeeze risk. No borrow availability or fee is implied.

Peptide biotech

NVO strength contrasts with LLY

Market: NVO +3.71% to $48.66 and VKTX +2.83% to $34.17, while LLY fell 1.06% to $1,233.66. NVO closed at the high shown by CNBC's exchange cache; use a hold, not a chase. NVO
Retatrutide evidence: TRIUMPH-2 is a completed randomized, double-blind Phase 3 trial with 1,152 actual participants. Primary endpoints are percent body-weight change and an AHI endpoint in a subset at week 80; no outcome data are posted in the registry. NCT05929079
Risk: efficacy, GI/other safety, discontinuations, manufacturing, reimbursement, competition and label breadth. VKTX is small-cap, binary and financing-sensitive; its July S-3ASR is financing optionality, not proof of issuance. SEC

Ranked ideas — conditional; fewer is better

1Conditional bullish

ANET · Arista Networks (NYSE)

Risk class: large-cap, high-valuation AI networking · Classification: relative-strength long only on confirmation · Horizons: day trade before macro only if disciplined; 1–4 week after NVIDIA; 3–12+ months with continued revenue/FCF support. Direction uncertain.

Thesis/catalyst: ANET rose 1.48% to $190.94 Tuesday after losing only 0.27% Monday, outperforming the focus basket over the two-session shock/repair. NVIDIA guidance is the immediate demand read-through.

Evidence / counterargument: Nasdaq confirms the Aug. 25 close and 4.39M volume. Counter: price remains below Tuesday's intraday high, one/two-day relative strength is limited evidence, and customer concentration, competition, rates or a weak AI-capex guide can reverse it.

Entry/confirmation: hold $190 and reclaim the vendor-observed $193.15 Tuesday high with positive semiconductor breadth; avoid initiating immediately before 14:30 CEST macro. Invalidation/downside: close below $188; next references $185/$180. Event-gap risk is material. Nasdaq

Thesis Confidence 67

Risk 86

Opportunity 63

2Speculative relative-strength long

NVO · Novo Nordisk ADR (NYSE)

Risk class: large-cap pharmaceutical ADR; pipeline, currency and policy sensitive · Classification: momentum/repair only · Horizons: day trade and 1–4 week swing; 3–12+ months only after pipeline/valuation review. Direction uncertain.

Thesis/catalyst: NVO's +3.71% close at $48.66 materially outperformed both LLY and the broad market. The move can extend if $48 becomes support; obesity/diabetes pipeline updates remain longer-term drivers.

Evidence / counterargument: Nasdaq independently timestamps price and 15.53M volume to Aug. 25. Counter: the ADR remains below its $64.16 52-week high; a one-day rebound does not solve competition, pricing, manufacturing or pipeline execution.

Entry/confirmation: do not chase a gap; require $48 hold and a close above $49. Invalidation/downside: close below $47.50, then $46.90; use $45 as broader risk reference. Key risks are trial/regulatory surprises, reimbursement, FX and competitor data. Nasdaq

Thesis Confidence 64

Risk 76

Opportunity 60

1Avoid fresh pre-event risk

NVDA · NVIDIA (Nasdaq)

Risk class: mega-cap earnings-gap / high-duration · Classification: avoid fresh swing; no overnight short call · Horizons: day trade only before results; 1–4 weeks after earnings; 3–12+ months guidance/valuation dependent. Direction uncertain.

Thesis/catalyst: Tuesday's +2.19% rebound to $213.05 repaired Monday's loss only partly. Macro at 14:30 CEST and after-close earnings create independent two-way gaps.

Evidence / counterargument: Nasdaq confirms 122.3M volume, the close and tonight's earnings listing. Counter: profitable scale and a strong forward guide could lift the whole AI complex; weak guidance can overwhelm technical levels.

Entry/confirmation: no fresh overnight swing. Tactical action only if the post-macro move confirms; close before earnings. Invalidation: not applicable to an avoid classification; day references are $208.48 prior close and $215/$220 upside. Short loss is unlimited; no borrow claim. Nasdaq

Thesis Confidence 91

Risk 98

Opportunity 38

2Avoid / bearish on failed rebound

QBTS · D-Wave Quantum (Nasdaq)

Risk class: small/high-beta speculative quantum; squeeze and dilution prone · Classification: avoid chase; bearish only after failed rebound · Horizons: day trade; 1–4 week avoid/observe; no core 3–12+ month entry absent stronger commercial economics. Direction uncertain.

Thesis/catalyst: Tuesday's 3.59% rebound to $19.35 did not recover Monday's 8.39% fall. The CFO retirement/acting-CFO transition is an additional governance and execution monitor, though the company says there was no disagreement.

Evidence / counterargument: the Aug. 25 8-K is primary evidence; Nasdaq verifies price. Counter: an orderly internal transition, contracts, deployments or technical progress can trigger a sharp rally and real option value.

Entry/confirmation: no blind short; only a failed rebound and break below $18.68, then $18. Invalidation: sustained reclaim above $19.53/$20. Short losses are unlimited; availability/fees unknown. SEC

Thesis Confidence 70

Risk 97

Opportunity 45

No third bullish or bearish idea: same-day macro and NVIDIA earnings reduce evidence quality. Cash is a valid position.

Watchlist — maximum five

Ticker / risk class	Classification & horizon	Thesis / catalyst / counterargument	Confirmation / invalidation / key risks	C / R / O
Watch MRVL Nasdaq · high-beta custom silicon/networking	Earnings watch. Day/swing only after evidence; long term after guidance.	+4.84% to $240.38; NVIDIA tonight and MRVL Aug. 27 after close. Counter: two event gaps, customer concentration, valuation.	No pre-event chase. Post-results hold above $240/$246.70; invalidate below $235 then $229.29.	72 / 93 / 61
Watch VRT NYSE · high-beta AI power/cooling	Lagging repair. Day/swing after NVIDIA; long term fundamentals/valuation.	Only +0.31% to $255.75 versus Nasdaq +0.66%, after Monday's −2.66%. Counter: a strong infrastructure guide can rapidly restore momentum.	Reclaim $260 then vendor high $267.05; invalidate below $255/$250. Rates, project timing, event gap.	69 / 87 / 56
Watch AVGO Nasdaq · mega-cap AI/custom silicon	Relative-laggard watch. Day/swing after NVDA; 3–12 months after Sep. 2 earnings.	Fell 0.56% while semis rebounded. Counter: custom silicon/networking demand and VMware cash generation.	Reclaim $360/$363; invalidate below $355/$350. Customer concentration, leverage, valuation.	65 / 84 / 55
Watch LLY / VKTX NYSE / Nasdaq · large-cap and small-cap peptide	Divergence watch. Swing only; VKTX speculative/binary. Long term on clinical evidence.	LLY −1.06% to $1,233.66 while VKTX +2.83% to $34.17. Retatrutide Phase 3 registry is completed but has no posted results. Counter: pipeline optionality.	LLY reclaim $1,247; VKTX hold $33.43 and reclaim $35. VKTX invalidate below $33. Trial, safety, cash burn/dilution.	66 / 91 / 57
Watch CRM / SNPS NYSE / Nasdaq · cloud software and EDA	Earnings reaction only. Day Aug. 27; swing/long term after guidance.	Both report with NVIDIA tonight; CRM tests enterprise AI monetization, SNPS tests semiconductor design demand. Counter: consensus/gap and execution risk.	No pre-event levels-based call. Require guidance-backed post-gap hold and relative strength versus software/semis.	61 / 90 / 52

C / R / O = Thesis Confidence / Risk / Opportunity. Confidence measures evidence quality, not outcome probability.

Changes versus the 2026-08-25 report

Regime changes from neutral/cautious to neutral/event-risk: Tuesday's cash breadth and Asian gains improve the tape, but NQ futures are now −0.23% and the macro/NVIDIA sequence dominates.
ANET trigger partially confirmed: yesterday required reclaiming $190.25; ANET closed $190.94 (+1.48%). Because it did not hold above the vendor-observed $193.15 intraday high and NVIDIA remains ahead, the call stays conditional rather than counted as a full swing entry.
NVDA tactical bearish condition did not persist: NVDA rebounded 2.19% to $213.05. The core prior rule—no oversized carry through earnings—remains unchanged and is the higher-quality call.
VRT and VKTX repaired but did not fully reverse prior invalidations: VRT +0.31% remains below $260; VKTX +2.83% reclaimed $33.47 but remains a binary small-cap watch, not automatically a new entry.
Quantum bounce reduces immediate downside momentum, but new QBTS governance monitoring is added: its CFO retires Sep. 2 and an internal executive becomes acting CFO; the filing states no disagreement.

Important catalysts: next 7–30 days

Aug. 26 · 14:30 CEST — GDP second estimate/profits + July income/outlays
Official simultaneous growth, profits, income and PCE information. No result was available at cutoff. BEA

Aug. 26 · after U.S. close — NVIDIA, CRWD, CRM, SNPS
AI compute, cloud/security, enterprise software and EDA read-through. Forecasts in Nasdaq's calendar are estimates, not guidance. Nasdaq

Aug. 27 · after U.S. close — Marvell
Custom silicon/networking confirmation after NVIDIA. Nasdaq

Sep. 2 · D-Wave CFO transition / Broadcom expected earnings
QBTS acting CFO transition becomes effective; AVGO is expected to report, creating another AI infrastructure reset. QBTS SEC · AVGO Nasdaq

Sep. 3 · 14:30 CEST — U.S. July trade
Official BEA release; tariff effects and revisions matter. BEA

Sep. 15–16 · FOMC + projections
Statement, SEP and press conference can reprice yields and long-duration themes. Federal Reserve

Pipeline watch · timing not yet company-confirmed
TRIUMPH-2 is completed, but ClinicalTrials.gov posts no results. Do not assign a result date until Lilly or the registry does. Registry

Bottom line by horizon

Day trade

Bias: neutral until 14:30 CEST data and the first 30–60 U.S. cash minutes. ANET is conditional above $193.15; NVO only on a controlled $48 hold/$49 break. Avoid carrying NVDA day trades through earnings.

Biggest risk: data/headline whipsaw. Invalidation: bullish bias fails if NQ loses 29,096 and 10Y pushes higher; improves if NQ reclaims 29,310 with broad semis.

1–4 week swing

Bias: light size; prefer post-event bases. ANET/NVO are the best conditional relative-strength candidates, not unconditional buys.

Biggest risk: NVIDIA guidance and rates reprice together. Invalidation: sustained S&P break below 7,650 worsens the setup; a close above 7,700 with improving breadth reduces caution.

3–12+ month investment

Bias: prefer profitable, cash-generative infrastructure; demand commercial economics for quantum and clinical/regulatory evidence for biotech. Keep speculative sleeves small.

Biggest risk: peak expectations under high yields. Invalidation: durable FCF acceleration, structurally lower long yields, or material clinical/commercial de-risking would justify higher exposure.

Data quality & methodology

Timestamp/session: generated Wednesday 08:33:58 CEST. CNBC exchange quote API was observed 08:21–08:34 CEST. U.S. cash indices and Nasdaq single-stock data are Aug. 25 closes; futures/rates/FX/commodities are overnight. Europe had not opened at the 08:30 nominal cutoff; Tuesday closes are shown. Asian quotes were late-session, not guaranteed official final closes.
Successful live retrievals: CNBC browser quote pages, direct quote API and RSS; Nasdaq quote/summary and earnings APIs; SEC submissions and full D-Wave 8-K; BEA schedule; Fed press feed/calendar; ClinicalTrials.gov API; Cboe VIX page. This exceeds the required five meaningful retrieval calls across market data, news and primary sources.
Cross-check: Nasdaq independently timestamped focus-stock prices Aug. 25 and matched the values returned by CNBC. CNBC's bulk single-stock cache incorrectly labeled those values Aug. 24, so Nasdaq dates are authoritative; CNBC intraday highs/lows are used only as vendor-observed reference levels and labeled accordingly.
Blocked/limited sources: Yahoo chart API returned HTTP 429; generic web search and web extraction failed for insufficient service credits; NVIDIA IR, D-Wave IR and BLS returned HTTP 403; Novo Nordisk IR had DNS failure; Lilly IR timed out. Alternatives succeeded: Nasdaq calendar/quotes and NVIDIA's public site, SEC filings, BEA/Fed, CNBC RSS/direct quotes, ClinicalTrials.gov and Cboe. No required dashboard field is declared unavailable.
News quality: CNBC RSS build time was 06:12 UTC. Primary sources support filing, trial and macro timing claims. Secondary reports are labeled and are not treated as company guidance.
Scoring: Confidence is evidence quality, never guaranteed probability. Risk rises with event gaps, valuation, liquidity, leverage, dilution, management transitions and binary exposure. Opportunity balances asymmetry, evidence and timing. Levels are paper-tracking triggers, not orders.

Sources

Research disclaimer: Research and paper-tracking only—not individualized, guaranteed, fiduciary, legal or medical advice. Initial two weeks are paper-tracking. Prices can gap beyond invalidation levels; shorts can lose more than invested. Verify quotes, liquidity, taxes and suitability independently.